510(k) Report

510(k) · Cleared

Cleared

Frontier X Plus

K240794510(k) TraditionalCleared Nov 8, 2024231-day reviewClass II21 CFR 870.2800

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Fourth Frontier Technologies Pvt, Ltd. · MLO Electrocardiograph, Ambulatory, With Analysis Algorithm

Cleared on Nov 8, 2024 as substantially equivalent to K201644 (Qardio, Inc., 2021) and 1 other predicate after a 231-day review. Its family tree reaches back 2 generations to 2012.

Decided
Nov 8, 2024
Review
231 days
Class
Class II
Product code
MLO
Recalls
None
Predicates
2

Its longest line of descent runs back 2 generations to K121319 (2012). 3 ancestors in all. No later device cites it as a predicate yet.

Other ancestors, by year cleared 2019: 1 other ancestorK121319 · Zio Patch · iRhythm Technologies, Inc. · 2012K201644 · QardioCore · Qardio, Inc. · 20212010201520202025
Other ancestors, by generation 1 generation back: 1 other ancestor K201644 · QardioCore · Qardio, Inc. · 2021K121319 · Zio Patch · iRhythm Technologies, Inc. · 20120
  1. Root · 2 generations backK121319 Zio PatchiRhythm Technologies, Inc. · 2012
  2. 1 generation backK201644 QardioCoreQardio, Inc. · 2021
  3. This deviceK240794 Frontier X PlusFourth Frontier Technologies Pvt, Ltd. · 2024
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−2K121319Zio PatchiRhythm Technologies, Inc.2012—
−1K201644QardioCoreQardio, Inc.2021—
0 (this device)K240794Frontier X PlusFourth Frontier Technologies Pvt, Ltd.2024—

Other ancestors by year cleared

Year clearedDevicesWith a Class I recall
201910
FIG. 1 — Lineage of K240794, 2012–2024Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in MLO? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new MLO device

  1. #1 K261580 ZBPro Diagnostic (Version 2.0)score 13.8 · 7 generations · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (2)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K201644QardioCore
Summary page 5
…rder Classification: 21 CFR§870.2800, Medical Magnetic Tape Recorder, Class II Product Code: MLO Subsequent Product Code(s): DXH , DPS PREDICATE DEVICE(S) [807.92(a)(3)] K201644 – QardioCore ECG Monitor (primary predicate device) Product code: DSH K182396 – AliveCor Heart Monitor (predicate device, curren…
Qardio, Inc.2021—
*K182396KardiaMobile, KardiaStation
Summary page 5
…Product Code: MLO Subsequent Product Code(s): DXH , DPS PREDICATE DEVICE(S) [807.92(a)(3)] K201644 – QardioCore ECG Monitor (primary predicate device) Product code: DSH K182396 – AliveCor Heart Monitor (predicate device, currently marketed as “KardiaMobile”) Product code: DXH, DPS…
AliveCor, Inc.2019—

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 12 years and passes through 3 companies; a new generation was cleared every 8.6 years on median.
  • None of the 3 ancestors has a recall.

How does its category compare?

All MLO devices

MLO Electrocardiograph, Ambulatory, With Analysis Algorithm: FDA decisions, review times, recalls and adverse event reports over 20 years. 2024, this device’s year, is highlighted.

FDA decisions per year · MLO

1in 2025

2007: 12010: 12011: 32012: 12013: 22014: 12018: 12020: 22024: 12025: 12026 (partial year): 1
2007high 3 (2011) · low 0 (2008)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · MLO

238in 2011

2011: 238 days median
2007high 238 (2011)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · MLO

2in 2024

2024: 2
2007high 2 (2024) · low 0 (2007)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · MLO

4in 2025

2009: 52010: 12011: 12014: 12017: 12018: 12019: 12021: 12022: 12023: 12024: 22025: 4
2007high 5 (2009) · low 0 (2007)2025

MAUDE reports naming product code MLO, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20071—00
20080—00
20090—05
20101—01
2011323801
20121—00
20132—00
20141—01
20150—00
20160—00
20170—01
20181—01
20190—01
20202—00
20210—01
20220—01
20230—01
20241—22
20251—04
20261—0—

What is it indicated for?

The Frontier X Plus device is an ambulatory monitoring device intended to record, store, and transfer single-channel (ECG) rhythms for monitoring and evaluation. The Frontier X Plus system also displays ECG waveforms and ECG rhythm analysis; detecting the presence of normal sinus rhythm, atrial fibrillation, bradycardia, tachycardia, inconclusive and unreadable rhythm. The Frontier X Plus is intended for use by healthcare professionals, patients with…

Read the full statement (133 words)

The Frontier X Plus device is an ambulatory monitoring device intended to record, store, and transfer single-channel (ECG) rhythms for monitoring and evaluation. The Frontier X Plus system also displays ECG waveforms and ECG rhythm analysis; detecting the presence of normal sinus rhythm, atrial fibrillation, bradycardia, tachycardia, inconclusive and unreadable rhythm. The Frontier X Plus is intended for use by healthcare professionals, patients with known or suspected heart conditions and health-conscious individuals. It is indicated for use on adult patients who may be asymptomatic or who may suffer from transient symptoms requiring cardiac monitoring. The device has not been tested for pediatric use. The Frontier X Plus is a prescription-only device, and the reported information is provided for review by a physician who will render a diagnosis based on clinical judgment and experience.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K240794: Frontier X Plus.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 5, 2026. https://510kreport.com/device/K240794

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026